Form 8-K - Current report:
SEC Accession No. 0000950170-23-067461
Filing Date
2023-12-04
Accepted
2023-12-04 06:04:40
Documents
14
Period of Report
2023-11-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K idya-20231129.htm   iXBRL 8-K 44584
2 EX-99.1 idya-ex99_1.htm EX-99.1 13694
3 GRAPHIC img107722786_0.jpg GRAPHIC 2663
  Complete submission text file 0000950170-23-067461.txt   189117

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT idya-20231129.xsd EX-101.SCH 2467
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT idya-20231129_lab.xml EX-101.LAB 14940
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT idya-20231129_pre.xml EX-101.PRE 11427
8 EXTRACTED XBRL INSTANCE DOCUMENT idya-20231129_htm.xml XML 4901
Mailing Address 7000 SHORELINE COURT, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 7000 SHORELINE COURT, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-443-6209
IDEAYA Biosciences, Inc. (Filer) CIK: 0001676725 (see all company filings)

EIN.: 474268251 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38915 | Film No.: 231461204
SIC: 2834 Pharmaceutical Preparations